| Literature DB >> 30369887 |
Abstract
Skeletal muscle is able to modify its size, and its metabolic/contractile properties in response to a variety of stimuli, such as mechanical stress, neuronal activity, metabolic and hormonal influences, and environmental factors. A reduced oxygen availability, called hypoxia, has been proposed to induce metabolic adaptations and loss of mass in skeletal muscle. In addition, several evidences indicate that muscle fiber-type composition could be affected by hypoxia. The main purpose of this review is to explore the adaptation of skeletal muscle fiber-type composition to exposure to high altitude (ambient hypoxia) and under conditions of pathological hypoxia, including chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF) and obstructive sleep apnea syndrome (OSAS). The muscle fiber-type composition of both adult animals and humans is not markedly altered during chronic exposure to high altitude. However, the fast-to-slow fiber-type transition observed in hind limb muscles during post-natal development is impaired in growing rats exposed to severe altitude. A slow-to-fast transition in fiber type is commonly found in lower limb muscles from patients with COPD and CHF, whereas a transition toward a slower fiber-type profile is often found in the diaphragm muscle in these two pathologies. A slow-to-fast transformation in fiber type is generally observed in the upper airway muscles in rodent models of OSAS. The factors potentially responsible for the adaptation of fiber type under these hypoxic conditions are also discussed in this review. The impaired locomotor activity most likely explains the changes in fiber type composition in growing rats exposed to severe altitude. Furthermore, chronic inactivity and muscle deconditioning could result in the slow-to-fast fiber-type conversion in lower limb muscles during COPD and CHF, while the factors responsible for the adaptation of muscle fiber type during OSAS remain hypothetical. Finally, the role played by cellular hypoxia, hypoxia-inducible factor-1 alpha (HIF-1α), and other molecular regulators in the adaptation of muscle fiber-type composition is described in response to high altitude exposure and conditions of pathological hypoxia.Entities:
Keywords: chronic heart failure; chronic obstructive pulmonary disease; hypoxia-inducible factor-1 alpha; muscle plasticity; myosin heavy chain; obstructive sleep apnea syndrome; oxygen
Year: 2018 PMID: 30369887 PMCID: PMC6194176 DOI: 10.3389/fphys.2018.01450
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
Adaptation of skeletal muscle fiber type in response to ambient and simulated hypoxia.
| Human | M | 21–31 y | 40 d, 0 → 8,848 m (decompression chamber) | VL | X vs. Before | Green et al., |
| M | 23 y | 3 w at 4,300 m (ambient hypoxia) | VL | X vs. before | Green et al., | |
| 18 y | High-altitude native Tibetans | VL | X vs. Nepalese lowlanders | Kayser et al., | ||
| M | 24.2 y | High-altitude natives of La Paz (Bolivia) | VL | No comparison with lowlanders | Desplanches et al., | |
| M, F | 22–31 y | 8 w at 4,100 m (El Alto, Bolivia) | VL | X vs. Before | Juel et al., | |
| M | 26–37 y | High-altitude natives of la Paz/El Alto (Bolivia) | VL | X vs. Caucasian lowlanders | ||
| M | 39 y | 23 d at > 5,000 m (expedition in the Himalayas) | VL | ↑ % FI and ↓ % FIIA, ↑ % MHC1 and ↓ % MHC2A vs. Before | Doria et al., | |
| Rat | F | Developing | 6 w at 5,100 m (normobaric hypoxia) | SOL | X vs. CT | Sillau and Banchero, |
| GAS, TA | ↑ % FII and ↓ % FI vs. CT | |||||
| 7 w at 4,000 m (hypobaric hypoxia) | SOL | ↑ % FOG and ↓ % SO vs. CT | Itoh et al., | |||
| M | 4 w | 10 w at 4,000 m (hypobaric hypoxia) | SOL | ↑ % FOG and ↓ % SO vs. CT | Itoh et al., | |
| EDL | ↑ % FOG and ↓ % FG vs. CT | |||||
| M | 5–6 w | 14 w at 4,000 m (hypobaric hypoxia) | SOL | X vs. CT | Bigard et al., | |
| EDL | ↑ % FIIA/IIB vs. CT | |||||
| PLA (deep) | ↑ % FIIA/IIB and ↓ % FIIA vs. CT | |||||
| M, F | Born in hypoxia | 30 w at 4,000 m (hypobaric hypoxia) | SOL | ↑ % FOG and ↓ % SO vs. CT | Hirofuji et al., | |
| M | 5 w | 7 w at 4,000 m (hypobaric hypoxia) | SOL | ↑ % FOG vs. CT | Itoh et al., | |
| M | 3 w | 12 w at 4,000 m (hypobaric hypoxia) | SOL | ↑ % FOG and ↓ % SO vs. CT | Itoh et al., | |
| M | 5, 10, and 15 w | 5 w at 4,000 m (hypobaric hypoxia) | SOL | ↓ % SO and ↓ % MHC1 in younger rats (5 and 10 w) vs. CT | Ishihara et al., | |
| M | 8 w | 8 w at 2,250–2,550 m (hypobaric hypoxia) | EDL | X vs. CT | Perhonen et al., | |
| M | 5 and 10 w | 4,000 m (hypobaric hypoxia): 5 w for younger rats, 10 w for older rats | EDL | ↑ % FOG and ↓ % FG in younger rats vs. CT, X in older rats vs. CT | Ishihara et al., | |
| M | 3–4 w | 4 w at 5,500 m (hypobaric hypoxia) | SOL | ↑ % FIIA and ↓ % FI, ↑ % MHC2A and ↓ % MHC1 vs. CT | Bigard et al., | |
| PLA | ↓ % FI and FIIA, ↑ % FIIB vs. CT | |||||
| M | 5–6 w | 3 w at 4,000 m (normobaric hypoxia) | SOL, EDL, TA | X vs. CT | Deveci et al., | |
| M | 11 w | 4 w at 5,500 m (normobaric hypoxia) | SOL | ↑ % FIIA and ↓ % FI vs. CT | Faucher et al., | |
| EDL | ↓ % FIIX vs. CT | |||||
| F | 8–9 w | 53 d at 5,500 m (hypobaric hypoxia) | PLA | X vs. CT | Chaillou et al., | |
| F | 8–9 w | 35 d at 5,500 m (hypobaric hypoxia) | SOL | X vs. CT | Chaillou et al., | |
| M | 7 w | 7.5 h/d (11.5% O2) for 2 d or 4 d (normobaric hypoxia) | SOL | X vs. CT | Nguyen et al., | |
| TA | X vs. CT | |||||
| GH | In single fibers: ↓% MHC2A, ↑% MHC2A/2B, and ↑% MHC2B vs. CT | |||||
| Mouse | M | 4, 12, and 52 w | 3 w at 8% O2 (normobaric hypoxia) | SOL | ↑ % FI/IIA and ↓ % FIIA in young mice vs. CT | Slot et al., |
| EDL | X vs. CT | |||||
| M | 8–10 w | 4 w at 10 % O2 (normobaric hypoxia) | SOL | ↓ % FIIX and FIIB vs. CT | Shin et al., | |
| GAS | ↑ % FIIA, ↓ % FIIX and FIIB vs. CT | |||||
| High-altitude native mice | GAS | ↑ % FI vs. low-altitude native mice | Scott et al., | |||
| M, F | Adult | High-altitude native mice bred and raised in N | GAS | ↑ % FI vs. low-altitude native mice | Lui et al., | |
| 6–8 w at 4,300 m (hypobaric hypoxia) | GAS | X vs. CT | ||||
| M, F | Adult | High-altitude native mice bred and raised in N | Core GAS | X vs. low-altitude native mice | Mahalingam et al., | |
| 6–10 w at 4,300 m (hypobaric hypoxia) | Core GAS | ↓ % FI vs. CT | ||||
| M, F | 6–12 mo | High-altitude native mice bred and raised in N | DIA | X vs. low-altitude native mice | Dawson et al., | |
| 6–8 w at 4,300 m (hypobaric hypoxia) | DIA | ↓ % FIIA vs. CT | ||||
| M | 7 w | 4 w at 10 % O2 (normobaric hypoxia) | SOL | ↑ % FII and ↓ % FI vs. CT | O'Brien et al., |
M, male; F, female; y, year; mo, month, w, week; d, day; m, meter; N, normoxia; VL, vastus lateralis muscle; SOL, soleus muscle; GAS, gastrocnemius muscle; TA, tibialis anterior muscle; EDL, extensor digitorum longus muscle; PLA, plantaris muscle; GH, geniohyoid muscle; DIA, diaphragm muscle; X, not significantly different; ↑, increase; ↓, decrease; CT, control group; FI, type-I fiber; FIIA, type-IIA fiber; FIIA/IIB, type-IIA/IIB fiber; FIIX, type-IIX fiber; FIIB, type-IIB fiber; SO, Slow-twitch oxidative fiber; FOG, fast-twitch oxidative glycolytic fiber; FG, Fast-twitch glycolytic fiber; MHC1, myosin heavy chain 1; MHC2A, myosin heavy chain 2A; MHC2A/2B, myosin heavy chain 2A/2B; MHC2B, myosin heavy chain 2B. The age of the animals presented in the table corresponds to the age at the beginning of the experiments.
Adaptation of skeletal muscle fiber type under conditions of pathological hypoxia.
| COPD | Human | M | Stable COPD (predicted FEV1: 62%) | 66 y | QUA | ↓% FI and ↑% FIIX vs. CT. After haemodilution, ↑% FI and ↓ % FIIX | Hildebrand et al., |
| M | Stable COPD (predicted FEV1: <70%) | 65 y | VL | ↑ % MHC2X vs. CT | Satta et al., | ||
| M, F | Stable COPD (predicted FEV1: 33%) | 59 y | DIA | ↑ % MHC1 and FI, ↓ % MHC2A, ↓ % MHC2X and FIIX vs. CT | Levine et al., | ||
| M, F | Stable COPD (predicted FEV1: 37%) | 65 y | VL | ↓ % FI and ↑ % FIIX vs. CT | Whittom et al., | ||
| M | Stable COPD (predicted FEV1: 31%) | 65 y | VL | ↓ % MHC1 and ↑ % MHC2A vs. CT | Maltais et al., | ||
| M | Stable COPD (predicted FEV1: 55%) | 63 y | DEL | X vs. CT | Gea et al., | ||
| M, F | Stable COPD (predicted FEV1: 65%) | 65 y | DIA | ↑ % FI and ↓ % FIIA vs. CT | Doucet et al., | ||
| VL | X vs. CT | ||||||
| M, F | Chronic Obstructive Lung Disease stage II-IV (predicted FEV1: ~40%) | 58–67 y | QUA | ↑ % FIIX vs. CT | Remels et al., | ||
| M, F | Stable COPD (predicted FEV1: 41%) | 68 y | VL | ↓ % FI, ↑ % FIIA and ↑ % FIIX vs. CT | Natanek et al., | ||
| M | Chronic Obstructive Lung Disease stage III-IV (predicted FEV1: 26–36%) | 66 y | VL | ↓ % FI and ↑ % FII vs. CT | Thériault et al., | ||
| M, F | Stable COPD (predicted FEV1: 57 % in nonsarcopenic COPD, 42% in sarcopenic COPD) | Sarcopenic: 68 y; nonsarcopenic: 65 y | VL | ↓ % FI, ↑ % FII vs. CT. ↓ % FI in sarcopenic COPD vs. nonsarcopenic COPD | van de Bool et al., | ||
| M, F | Stable COPD (predicted FEV1: 39 % in F, 40 % in M) | F: 63 y; M: 66 y | VL | ↓ % FI and ↑ % FII vs. CT | Ausin et al., | ||
| M | Stable COPD (predicted FEV1: 42 % in nonsarcopenic COPD, 29 % in sarcopenic COPD) | Sarcopenic and nonsarcopenic: 65 y | VL | ↓ % FI vs. CT. ↑ % FIIA/IIX in sarcopenic COPD vs. CT | Kapchinsky et al., | ||
| CHF | Human | M | Coronary artery disease or cardiomaopathy | 57 y | GAS | ↑ % FIIX vs. CT | Mancini et al., |
| M | Left ventricular systolic dysfunction | 58 y | VL | ↓ % FI and ↑ % FIIX vs. CT | Sullivan et al., | ||
| M | Coronary artery disease, idiopathic dilated cardiomyopathy | 56 y | VL | ↓ % FI and ↑ % FII vs. CT | Drexler et al., | ||
| M, F | Ischemic heart disease or dilated cardiomyopathy | 58 y | VL | ↑ % FIIx vs. CT | Schaufelberger et al., | ||
| M, F | Left ventricular systolic dysfunction | 48 y | VL | ↓ % FI, ↑ % FIIX vs. CT | Lindsay et al., | ||
| DIA | X vs. CT | ||||||
| PEC | ↓ % FI vs. CT | ||||||
| STE | X vs. CT | ||||||
| M | Left ventricular systolic dysfunction | 61 y | VL | ↓ % MHC1 and ↑ % MHC2X vs. CT | Sullivan et al., | ||
| M, F | Dilated cardiomyopathy or coronary artery disease | 50 y | DIA | ↑ % MHC1 and ↓ % MHC2X vs. CT | Tikunov et al., | ||
| M, F | CHF with preserved ejection fraction | 70 y | VL | ↓ % FI and ↑ % FII vs. CT | Kitzman et al., | ||
| Mouse | Dilated cardiomyopathy model: deletion mutation K210 in cardiac troponin T gene | 2 m | QUA | ↓ mRNA levels of | Okada et al., | ||
| SOL | ↓ mRNA levels of | ||||||
| Rat | F | Ligation of the left main coronary artery | Adult | SOL | X vs. CT | Delp et al., | |
| PLA | ↓ % FIIX and ↑ % FIIB vs. CT | ||||||
| F | Dahl salt-sensitive rats with high-salt diet | 35 w | SOL | X vs. CT | Bowen et al., | ||
| DIA | ↑ % FI, ↓ % FIIA vs. CT | ||||||
| M | Obese diabetic ZSF1 rats (preserved ejection fraction) | 20 w | DIA | ↑ % FI, ↓ % FII vs. CT | Bowen et al., | ||
| Minipig | M | Pacing-induced supraventricular tachycardia | 6 m | DIA | ↑ % FI, ↓ % FIIA vs. CT | Howell et al., | |
| LD | X vs. CT | ||||||
| OSAS | Human | Laryngeal carcinoma | 56 y | MPCM | ↓ % FI, ↑ % FIIA vs. CT | Ferini-Strambi et al., | |
| VL | X vs. CT | ||||||
| M, F | Recently diagnosed | 39 y | TA | Slight ↑ % FIIX and FIIA/IIX vs. CT | Wåhlin Larsson et al., | ||
| M | severe OSAS | 40 y | PAL | ↓ levels of MHC1 | Chen et al., | ||
| Rat | 15 s 6–8% O2, 10–14% CO2 /15 s N, 8 h/ d, 5d/ w for 5 w | GH | ↓ % FI and ↑ % FIIB vs. CT | McGuire et al., | |||
| STER | ↑ % FI, ↑ % FIIA, ↓ % FIIB vs. CT | ||||||
| M | 15 s 0 % O2/15 s N, 8 h/ d, 5d/ w for 5 w | SOL | X vs. CT | McGuire et al., | |||
| EDL | Slight ↑ % FIIA vs. CT | ||||||
| M | 240 s 10.3 % O2 /240 s N, 7.5 h/ d, for 4 d | Adult | GH | Single fibers: transition from MHC2A to MHC2B | Pae et al., | ||
| DIA | X vs. CT | ||||||
| STE | Single fibers: transition from MHC2A/2B to MHC2B | ||||||
| M | 90 s 5% O2 /90 s N, 8 h/d, for 7 d | Adult | STE | X vs. CT | Shortt et al., | ||
| DIA | ↓ % FI, ↑ % FIIB vs. CT | ||||||
| SOL | X vs. CT | ||||||
| EDL | X vs. CT | ||||||
| M | 4 min 10.3% O2/4 min N, 7.5 h/d, for 2 or 4 d | 7 w | SOL | X vs. CT | Nguyen et al., | ||
| TA | X vs. CT |
COPD, chronic obstructive pulmonary disease; CHF, chronic heart failure; OSAS, obstructive sleep apnea syndrome; M, male; F, female; FEV1, forced expiratory volume in the first second; ZSF1, Zucker fatty/spontaneously hypertensive heart failure F1 hybrid; y, year; m, month; w, week; d, day; s, second; N, normoxia; QUA, quadriceps muscle; VL, vastus lateralis muscle; DIA, diaphragm muscle; DEL, deltoid muscle; GAS, gastrocnemius muscle; PEC, pectoralis muscle; STE, sternohyoid muscle; LD, latissimus dorsi muscle; PAL, palatopharyngeus muscle; SOL, soleus muscle; TA, tibialis anterior muscle; EDL, extensor digitorum longus muscle; GH geniohyoid muscle; MPCM, medium pharyngeal constrictor muscle; X, not significantly different; ↑, increase; ↓, decrease; CT, control group; FI, type-I fiber; FIIA, type-IIA fiber; FIIX, type-IIX fiber; FIIB, type-IIB fiber; FIIA/IIX, type-IIA/IIX fiber; MHC1, myosin heavy chain 1; MHC2A, myosin heavy chain 2A; MHC2X, myosin heavy chain 2X; MHC2B, myosin heavy chain 2B; MHC2A/2B, myosin heavy chain 2A/2B; Myh7, myosin heavy chain 7 (encoding MHCI); Myh2, myosin heavy chain 2 (encoding MHCIIA); Myh4, myosin heavy chain 4 (encoding MHCIIB).
Figure 1Potential factors responsible for the adaptation of skeletal muscle fiber type in response to chronic exposure to high altitude and under conditions of pathological hypoxia. COPD, chronic obstructive pulmonary disease; CHF, chronic heart failure; OSAS, obstructive sleep apnea syndrome; ERR- α, estrogen related receptor-alpha. Vertical arrow, activation; Vertical blunt arrow, inhibition; ↘, decrease.
: Factor most likely responsible.
: Factor possibly responsible.
: Factor most unlikely responsible.
: Role played unclear or unknown.